cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.17632/cn3pz62cgj.1
title: Implant strength contributes to the osseointegration strength of porous metallic metals

description: This data is the accompanying data for the manuscript 'Implant strength contributes to the osseointegration strength of porous metallic metals' which describes an FEA model used to replicate and understand experimental data from an in-vivo push-out osseointegration model. The data found in this file can be used to recreate the plots found in the manuscript.
DOI: 10.17632/2zmtzfdzx2.1
title: Salud mental Villavicencio 2018

description: El siguiente Dataset contiene datos sobre los principales diagnósticos clínicos en salud mental atendidos durante el 2018 en la ciudad de Villavicencio.
DOI: 10.17632/m62wtn88ch.1
title: Supplementary materials for "Utility of nailfold capillary assessment for predicting pustulotic arthro-osteitis in palmoplantar pustulosis based on a prospective cohort study"

description: These data are supplementary materials for "Utility of nailfold capillary assessment for predicting pustulotic arthro-osteitis in palmoplantar pustulosis based on a prospective cohort study"
DOI: 10.6084/m9.figshare.22811765
title: Changes in NPX values

description: Description The archive contains files with the changes (delta) in NPX values (one file for each of the four contrasted timepoints). dNPX_accpost Represent the effect of acclimation in the hyperthermic state. It was generated by subtracting the NPX values on day 1 (post) [<strong>hyperthermic, pre-acclimation</strong>] from the NPX values on day 7 (post) [<strong>hyperthermic, post-acclimation</strong>]. dNPX_accpre Represent the effect of acclimation in the normothermic state. It was generated by subtracting the NPX values on day 1 (pre) [<strong>normothermic, pre-acclimation</strong>] from the NPX values on day 7 (pre) [<strong>normothermic, post-acclimation</strong>]. dNPX_hd1 Represent the effect of heat exposure prior to acclimation. It was generated by subtracting the NPX values on day 1 (pre) [<strong>normothermic, pre-acclimation</strong>] from the NPX values on day 1 (post) [<strong>hyperthermic, pre-acclimation</strong>]. dNPX_hd7 Represent the effect of heat exposure post-acclimation. It was generated by subtracting the NPX values on day 7 (pre) [<strong>normothermic, post-acclimation</strong>] from the NPX values on day 7 (post) [<strong>hyperthermic, post-acclimation</strong>].
DOI: 10.17632/33p9prx6sn.1
title: megalepidurus

description: Registros de ecología térmica
DOI: 10.25573/data.23736975.v1
title: Data for Boulder Diversity in the Nightingale Region of Asteroid (101955) Bennu and Predictions for Physical Properties of the OSIRIS-REx Sample

description: Dataset accompanying Manuscript titled Boulder Diversity in the Nightingale Region of Asteroid (101955) Bennu and Predictions for Physical Properties of the OSIRIS-REx Sample. Table includes data associated with each boulder mapped and analyzed in the region near the Nightingale sample site, including boulder ID, max diameter, central coordinates, morphologic data, morphologic type, and mean PolyCam albedo. For more information about the dataset, classification system, and morphologic codes, please see the full paper.
DOI: 10.6084/m9.figshare.21397158.v29
title: South African LNCS papers 1973-2022

description: This study investigated the research participation of South African (RSA) authors in LNCS for the period 1973 to 2022.
DOI: 10.17632/h9kznbnbvy.1
title: Project 5 - Technology for Mental Illness (UX Journey with Generative AI)

description: A UX journey case study involves a comprehensive analysis of the user experience for a specific product or service. The case study would likely include a description of the problem or opportunity that the product/service is intended to address, the target user group, and the context in which the product/service is used.

The case study would also include a detailed description of the design process, including user research, prototyping, testing, and iteration. This would involve identifying user needs and preferences, creating wireframes and mockups, and conducting user testing to refine the design. 

This data is a dataset from a pilot experiment to analyze the productivity of novice developers. In Project 5 with the topic Technology for Mental Illness, developers are asked to do an analysis using UX Journey and AI Generative. The structure of this data set consists of:
1. Original file: Initial analysis file from novice developer.
2. Revision 1: The result of the first improvement of several substantial notes.
3. Revision 2: The result of the second improvement from several substantial notes.
4. Revision 3: The result of the third improvement from several substantial notes.
5. Evaluation Rubric: Tests conducted by novice developers, through self-reviews, peer reviews, and walkthrough evaluations.
6. Self Efficacy: Results of the General Self Efficacy Scale questionnaire
7. Time and User Stories: Recap the time the respondents need to work on and the results of the user stories collected.
DOI: 10.17632/h9kznbnbvy.2
title: Project 5 - Technology for Mental Illness (UX Journey with Generative AI)

description: A UX journey case study involves a comprehensive analysis of the user experience for a specific product or service. The case study would likely include a description of the problem or opportunity that the product/service is intended to address, the target user group, and the context in which the product/service is used.

The case study would also include a detailed description of the design process, including user research, prototyping, testing, and iteration. This would involve identifying user needs and preferences, creating wireframes and mockups, and conducting user testing to refine the design. 

This data is a dataset from a pilot experiment to analyze the productivity of novice developers. In Project 5 with the topic Technology for Mental Illness, developers are asked to do an analysis using UX Journey and AI Generative. The structure of this data set consists of:
1. Original file: Initial analysis file from novice developer.
2. Revision 1: The result of the first improvement of several substantial notes.
3. Revision 2: The result of the second improvement from several substantial notes.
4. Revision 3: The result of the third improvement from several substantial notes.
5. Evaluation Rubric: Tests conducted by novice developers, through self-reviews, peer reviews, and walkthrough evaluations.
6. Self Efficacy: Results of the General Self Efficacy Scale questionnaire
7. Time and User Stories: Recap the time the respondents need to work on and the results of the user stories collected.
DOI: 10.17632/52bmtrhsct.1
title: Project 4 - Technology for Elderly (UX Journey with Generative AI)

description: A UX journey case study involves a comprehensive analysis of the user experience for a specific product or service. The case study would likely include a description of the problem or opportunity that the product/service is intended to address, the target user group, and the context in which the product/service is used.

The case study would also include a detailed description of the design process, including user research, prototyping, testing, and iteration. This would involve identifying user needs and preferences, creating wireframes and mockups, and conducting user testing to refine the design. 

This data is a dataset from a pilot experiment to analyze the productivity of novice developers. In Project 4 with the topic Technology for Elderly, developers are asked to do an analysis using UX Journey and AI Generative. The structure of this data set consists of:
1. Original file: Initial analysis file from novice developer.
2. Revision 1: The result of the first improvement of several substantial notes.
3. Revision 2: The result of the second improvement from several substantial notes.
4. Revision 3: The result of the third improvement from several substantial notes.
5. Evaluation Rubric: Tests conducted by novice developers, through self-reviews, peer reviews, and walkthrough evaluations.
6. Self Efficacy: Results of the General Self Efficacy Scale questionnaire
7. Time and User Stories: Recap the time the respondents need to work on and the results of the user stories collected.
DOI: 10.6084/m9.figshare.22811903.v1
title: The summary statistics

description: The summary statistics of the different analysis (OLS, LMM and Strip-Plot).
DOI: 10.17632/gzxv4sdk2k.1
title: data on improving optimum adsorption corrosion inhibition of AISI 4140 Steel by induce acidify Carica papaya leaf extract 

description: Data on RSM and ANN for adsorption study of green extract from C. papaya leaf CR and IE
DOI: 10.17632/2672vmdmkt.1
title: Project 3 - Technology for Child (UX Journey)

description: A UX journey case study involves a comprehensive analysis of the user experience for a specific product or service. The case study would likely include a description of the problem or opportunity that the product/service is intended to address, the target user group, and the context in which the product/service is used.

The case study would also include a detailed description of the design process, including user research, prototyping, testing, and iteration. This would involve identifying user needs and preferences, creating wireframes and mockups, and conducting user testing to refine the design. 

This data is a dataset from a pilot experiment to analyze the productivity of novice developers. In Project 3 with the topic Technology for Child, developers are asked to do an analysis using UX Journey. The structure of this data set consists of:
1. Original file: Initial analysis file from novice developer.
2. Revision 1: The result of the first improvement of several substantial notes.
3. Revision 2: The result of the second improvement from several substantial notes.
4. Revision 3: The result of the third improvement from several substantial notes.
5. Evaluation Rubric: Tests conducted by novice developers, through self reviews, peer reviews, and walkthrough evaluations.
6. Self Efficacy: Results of the General Self Efficacy Scale questionnaire
7. Time and User Stories: Recap the time the respondents need to work on and the results of the user stories collected.
DOI: 10.17632/2672vmdmkt.2
title: Project 3 - Technology for Child (UX Journey)

description: A UX journey case study involves a comprehensive analysis of the user experience for a specific product or service. The case study would likely include a description of the problem or opportunity that the product/service is intended to address, the target user group, and the context in which the product/service is used.

The case study would also include a detailed description of the design process, including user research, prototyping, testing, and iteration. This would involve identifying user needs and preferences, creating wireframes and mockups, and conducting user testing to refine the design. 

This data is a dataset from a pilot experiment to analyze the productivity of novice developers. In Project 3 with the topic Technology for Child, developers are asked to do an analysis using UX Journey. The structure of this data set consists of:
1. Original file: Initial analysis file from novice developer.
2. Revision 1: The result of the first improvement of several substantial notes.
3. Revision 2: The result of the second improvement from several substantial notes.
4. Revision 3: The result of the third improvement from several substantial notes.
5. Evaluation Rubric: Tests conducted by novice developers, through self reviews, peer reviews, and walkthrough evaluations.
6. Self Efficacy: Results of the General Self Efficacy Scale questionnaire
7. Time and User Stories: Recap the time the respondents need to work on and the results of the user stories collected.
DOI: 10.6084/m9.figshare.23737062
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23737062.v1
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23737071
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23737071.v1
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.17632/6hr3w4vz6r.1
title: Project 2 - Flight Booking System (UX Journey)

description: A UX journey case study involves a comprehensive analysis of the user experience for a specific product or service. The case study would likely include a description of the problem or opportunity that the product/service is intended to address, the target user group, and the context in which the product/service is used.

The case study would also include a detailed description of the design process, including user research, prototyping, testing, and iteration. This would involve identifying user needs and preferences, creating wireframes and mockups, and conducting user testing to refine the design. 

This data is a dataset from a pilot experiment to analyze the productivity of novice developers. In Project 2 with the topic Train Flight Booking System, developers are asked to do an analysis using UX Journey. The structure of this data set consists of:
1. Original file: Initial analysis file from novice developer.
2. Revision 1: The result of the first improvement of several substantial notes.
3. Revision 2: The result of the second improvement from several substantial notes.
4. Revision 3: The result of the third improvement from several substantial notes.
5. Evaluation Rubric: Tests conducted by novice developers, through self reviews, peer reviews, and walkthrough evaluations.
6. Self Efficacy: Results of the General Self Efficacy Scale questionnaire
7. Time and User Stories: Recap the time respondents need to work on and the results of the user stories collected.